Spironolactone plus patiromer: proceed with caution

Affiliations

¹ Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA. Electronic address: calyani@stanford.edu.
² Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA; Department of Urology, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

Comment

Calyani Ganesan et al. Lancet. 2019.

. 2019 Oct 26;394(10208):1486-1488.

doi: 10.1016/S0140-6736(19)32485-7.

¹ Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA. Electronic address: calyani@stanford.edu.
² Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA; Department of Urology, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

No abstract available

Comment on

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.

1. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394: 1540–50. - PubMed
1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–26. - PubMed
1. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059–68. - PMC - PubMed
1. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomised trial of intensive versus standard blood pressure control. N Engl J Med 2015; 373: 2103–16. - PMC - PubMed
1. Bushinsky DA, Spiegel DM, Yuan J, Warren S, Fogli J, Pergola PE. Effects of the potassium-binding polymer patiromer on markers of mineral metabolism. Clin J Am Soc Nephrol 2019; 14: 103–10. - PMC - PubMed